Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Mikus

Showing results (21-30 of 86) with videos related to

Pageof 9
Sort By:
British Journal of Clinical Pharmacology|August 5, 1998
Variability in the frequency of cytochrome P450-2D6 (CYP2D6) deficiencyK Mörike, H P Platten, G Mikus, et al.
European Journal of Clinical Pharmacology|January 1, 1991
Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pHA S Gross, G Mikus, C Fischer, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|November 1, 1991
Thebaine O-demethylation to oripavine: genetic differences between two rat strainsG Mikus, A A Somogyi, F Bochner, et al.
Biochemical Pharmacology|March 1, 1991
Codeine O-demethylation: rat strain differences and the effects of inhibitorsG Mikus, A A Somogyi, F Bochner, et al.
British Journal of Clinical Pharmacology|February 15, 2000
Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosingA S Gross, M Eichelbaum, K Mörike, et al.
Clinical Pharmacology and Therapeutics|October 1, 1995
Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humansM F Fromm, U Hofmann, E U Griese, et al.
British Journal of Clinical Pharmacology|November 1, 1987
Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administrationG Mikus, C Fischer, B Heuer, et al.
Annals of the Academy of Medicine, Singapore|January 1, 1991
Polymorphic metabolism of opioid narcotic drugs: possible clinical implicationsG Mikus, A A Somogyi, F Bochner, et al.
Journal of Thrombosis and Haemostasis : JTH|March 5, 2008
Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trialsJ Harenberg, Y Vukojevic, G Mikus, et al.
Clinical Pharmacology and Therapeutics|April 4, 2013
Cytochrome P450-3A phenotyping using midazolam is not altered by OATP1B1 polymorphismsV C Ziesenitz, J Weiss, W E Haefeli, et al.
Pageof 9

Showing results (21-30 of 86) with videos related to

Sort By:
Pageof 9
British Journal of Clinical Pharmacology|August 5, 1998
Variability in the frequency of cytochrome P450-2D6 (CYP2D6) deficiencyK Mörike, H P Platten, G Mikus, et al.
European Journal of Clinical Pharmacology|January 1, 1991
Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pHA S Gross, G Mikus, C Fischer, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|November 1, 1991
Thebaine O-demethylation to oripavine: genetic differences between two rat strainsG Mikus, A A Somogyi, F Bochner, et al.
Biochemical Pharmacology|March 1, 1991
Codeine O-demethylation: rat strain differences and the effects of inhibitorsG Mikus, A A Somogyi, F Bochner, et al.
British Journal of Clinical Pharmacology|February 15, 2000
Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosingA S Gross, M Eichelbaum, K Mörike, et al.
Clinical Pharmacology and Therapeutics|October 1, 1995
Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humansM F Fromm, U Hofmann, E U Griese, et al.
British Journal of Clinical Pharmacology|November 1, 1987
Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administrationG Mikus, C Fischer, B Heuer, et al.
Annals of the Academy of Medicine, Singapore|January 1, 1991
Polymorphic metabolism of opioid narcotic drugs: possible clinical implicationsG Mikus, A A Somogyi, F Bochner, et al.
Journal of Thrombosis and Haemostasis : JTH|March 5, 2008
Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trialsJ Harenberg, Y Vukojevic, G Mikus, et al.
Clinical Pharmacology and Therapeutics|April 4, 2013
Cytochrome P450-3A phenotyping using midazolam is not altered by OATP1B1 polymorphismsV C Ziesenitz, J Weiss, W E Haefeli, et al.
Pageof 9